Ponesimod Combination Therapy for Relapse Reduction in Autoimmune Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lymphocyte-mediated immune system disorders, such as multiple sclerosis and autoimmune diseases, often require multiple medications with varying administration schedules and dosages, which can be complex and may not fully address the severity or frequency of relapses.
Innovation Solution
A pharmaceutical combination of ponesimod and either teriflunomide or leflunomide, administered either together or sequentially, to provide a synergistic effect in managing these disorders, simplifying treatment regimens while enhancing efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple medications with varying administration schedules and dosages are used to treat lymphocyte-mediated immune system disorders, then treatment efficacy can be improved, but treatment complexity increases
Solution Approach 1:
The patent combines ponesimod (a S1P1 receptor agonist) with teriflunomide or leflunomide (immunomodulating agents) into a single pharmaceutical combination therapy. This merging of multiple medications into one regimen maintains the synergistic efficacy of treating lymphocyte-mediated immune system disorders while simplifying the administration schedule and reducing treatment complexity for patients
2Reliability
If multiple medications are used to address severity and frequency of relapses, then treatment coverage is improved, but ease of operation deteriorates
Solution Approach 1:
By formulating ponesimod and teriflunomide/leflunomide as a combined pharmaceutical product, the patent enables patients to receive comprehensive treatment coverage for both severity and frequency of relapses through a single administration routine, significantly improving ease of operation and patient compliance
3Reliability
If combination therapy is implemented to enhance efficacy, then treatment outcomes improve, but safety profile may worsen
Solution Approach 1:
The patent optimizes the dosage parameters of ponesimod in combination with teriflunomide or leflunomide to achieve synergistic therapeutic effects while maintaining an acceptable safety profile. By carefully adjusting the dosage ratios and administration frequencies, the combination therapy enhances treatment outcomes for lymphocyte-mediated immune system disorders while managing potential adverse effects
Data Source
AI summary
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.